Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D 2 -Based Pharmacological Class Effect Query Defined by FAERS.

The cumulative curves of class-specific adverse events in risperidone clinical trials of schizophrenia were similar to those first reported for other atypical antipsychotic drugs. However, the class-specific adverse event curves were notably lower for Alzheimer's disease and higher for autism, suggesting that the diagnostic indication may have an important effect on the cumulative class-specific side-effect burden.